Welcome to Lipopharma, a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines based on the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT)

next-generation medicines!


Lipopharma aims to develop next-generation medicines based on the novel MLT strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs are designed to modulate key signal-transduction response pathways involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases.


Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, providing a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.

Latest news

Lipopharma announces IND approval by the FDA to proceed with a PhI paediatric trial assessing 2OHOA in children with advanced brain and other solid tumours

Following the positive conclusion of a PI/IIa trial in Europe with 2OHOA in adult patients with advanced solid tumours, including malignant glioma, this paediatric trial will investigate the safety profile and preliminary anticancer activity of this novel cell-membrane modulator in children with malignant glioma and other advanced solid tumours.

Palma de Mallorca (Spain) and Acton (MA, USA). May 29th 2018 – Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of products modulating metabolism of membrane lipids based on the groundbreaking MLT platform, announces that the FDA has approved an IND for a paediatric trial entitled “a phase I study of 2-hydroxyoleic acid (2OHOA) in pediatric patients with malignant glioma and other advanced solid tumors”

Read more ...

© 2019 Lipopharma Therapeutics. All rights reserved | legal notice

Ctra. de Valldemossa Km. 7,4. ParcBIT. Edifici Disset. 2n. Mod. C-8. E07121 - Palma de Mallorca. Spain  | Phone/Fax: +34 971439886  |  Email: